4 búsqueda de la palabra clave 'tumor'

Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? / Luis Vicente Syro Moreno    

Público ISBD Título : Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2021 Títulos uniformes : Journal of the Endocrine Society Idioma : Inglés (eng) Palabras clave : Pituitary neoplasm  neuroendocrine  pituitary adenoma  tumor Resumen : The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges. Mención de responsabilidad : Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, M Beatriz Lopes, Pamela Kunz, Mark Molitch, Sally A Camper, Mônica Gadelha, Luis V Syro, Edward Laws, Martin Reincke, Hiroshi Nishioka, Ashley Grossman, Ariel Barkan, Felipe Casanueva, John Wass, Adam Mamelak, Laurence Katznelson, Aart J van der Lely, Sally Radovick, Martin Bidlingmaier, Margaret Boguszewski, Jens Bollerslev, Andrew R Hoffman, Nelson Oyesiku, Gerald Raverot, Anat Ben-Shlomo, Rob Fowkes, Ilan Shimon, Hidenori Fukuoka, Alberto M Pereira, Yona Greenman, Anthony P Heaney, Mark Gurnell, Gudmundur Johannsson, Robert Y Osamura, Michael Buchfelder, Maria Chiara Zatelli, Marta Korbonits, Philippe Chanson, Nienke Biermasz, David R Clemmons, Niki Karavitaki, Marcello D Bronstein, Peter Trainer, Shlomo Melmed Referencia : J Endocr Soc. 2021 Feb 9;5(3):bvaa205. DOI (Digital Object Identifier) : 10.1210/jendso/bvaa205 PMID : 33604494 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/jes/article/5/3/bvaa205/6131724 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5765 Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? [documento electrónico] / Luis Vicente Syro Moreno,  . - 2021. Obra : Journal of the Endocrine Society Idioma : Inglés (eng) Palabras clave : Pituitary neoplasm  neuroendocrine  pituitary adenoma  tumor Resumen : The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges. Mención de responsabilidad : Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, M Beatriz Lopes, Pamela Kunz, Mark Molitch, Sally A Camper, Mônica Gadelha, Luis V Syro, Edward Laws, Martin Reincke, Hiroshi Nishioka, Ashley Grossman, Ariel Barkan, Felipe Casanueva, John Wass, Adam Mamelak, Laurence Katznelson, Aart J van der Lely, Sally Radovick, Martin Bidlingmaier, Margaret Boguszewski, Jens Bollerslev, Andrew R Hoffman, Nelson Oyesiku, Gerald Raverot, Anat Ben-Shlomo, Rob Fowkes, Ilan Shimon, Hidenori Fukuoka, Alberto M Pereira, Yona Greenman, Anthony P Heaney, Mark Gurnell, Gudmundur Johannsson, Robert Y Osamura, Michael Buchfelder, Maria Chiara Zatelli, Marta Korbonits, Philippe Chanson, Nienke Biermasz, David R Clemmons, Niki Karavitaki, Marcello D Bronstein, Peter Trainer, Shlomo Melmed Referencia : J Endocr Soc. 2021 Feb 9;5(3):bvaa205. DOI (Digital Object Identifier) : 10.1210/jendso/bvaa205 PMID : 33604494 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/jes/article/5/3/bvaa205/6131724 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5765

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001690	AC-2021-016	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2021-016 Adobe Acrobat PDF

Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey / Luis Vicente Syro Moreno  

Público ISBD Título : Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2019 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Adenoma  Contrast  Gadolinium  Imaging  Neuroendocrinologists  Neurosurgeons  Pituitar  Safety  Survey  Tumor Resumen : Purpose: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. Methods: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. Results: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAsin patients with normal function. Conclusions: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice. Mención de responsabilidad : Lisa B Nachtigall, Niki Karavitaki, Katja Kiseljak-Vassiliades, Luma Ghalib, Hidenori Fukuoka, Luis V Syro, Daniel Kelly, Maria Fleseriu Referencia : Pituitary. 2019 Feb;22(1):37-45. DOI (Digital Object Identifier) : 10.1007/s11102-018-0924-0 PMID : 30456434 En línea : https://link.springer.com/article/10.1007%2Fs11102-018-0924-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4128 Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey [documento electrónico] / Luis Vicente Syro Moreno,  . - 2019. Obra : Pituitary Idioma : Inglés (eng) Palabras clave : Adenoma  Contrast  Gadolinium  Imaging  Neuroendocrinologists  Neurosurgeons  Pituitar  Safety  Survey  Tumor Resumen : Purpose: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. Methods: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. Results: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAsin patients with normal function. Conclusions: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice. Mención de responsabilidad : Lisa B Nachtigall, Niki Karavitaki, Katja Kiseljak-Vassiliades, Luma Ghalib, Hidenori Fukuoka, Luis V Syro, Daniel Kelly, Maria Fleseriu Referencia : Pituitary. 2019 Feb;22(1):37-45. DOI (Digital Object Identifier) : 10.1007/s11102-018-0924-0 PMID : 30456434 En línea : https://link.springer.com/article/10.1007%2Fs11102-018-0924-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4128

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000739	AC-2018-026	Archivo digital	Producción Científica	Artículos científicos	Disponible

Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy / Luis Vicente Syro Moreno  

Público ISBD Título : Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2011 Títulos uniformes : Anticancer Research Idioma : Inglés (eng) Palabras clave : Angiogenesis  cancer  CD105  endoglin  tumor  review Resumen : Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been suggested as an appropriate marker for tumor-related angiogenesis and neovascularization. Several studies demonstrate the potential of endoglin in tumor diagnosis, prognosis, and therapy. This review details the structure and function of endoglin, and investigates the role of endoglin in angiogenesis and tumor diagnosis, prognosis, and therapy. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, George M Yousef, Luis V Syro, Kalman Kovacs, Ricardo V Lloyd Referencia : Anticancer Res. 2011 Jun;31(6):2283-90. PMID : 21737653 En línea : http://ar.iiarjournals.org/content/31/6/2283.full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3555 Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy [documento electrónico] / Luis Vicente Syro Moreno,  . - 2011. Obra : Anticancer Research Idioma : Inglés (eng) Palabras clave : Angiogenesis  cancer  CD105  endoglin  tumor  review Resumen : Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been suggested as an appropriate marker for tumor-related angiogenesis and neovascularization. Several studies demonstrate the potential of endoglin in tumor diagnosis, prognosis, and therapy. This review details the structure and function of endoglin, and investigates the role of endoglin in angiogenesis and tumor diagnosis, prognosis, and therapy. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, George M Yousef, Luis V Syro, Kalman Kovacs, Ricardo V Lloyd Referencia : Anticancer Res. 2011 Jun;31(6):2283-90. PMID : 21737653 En línea : http://ar.iiarjournals.org/content/31/6/2283.full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3555

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000124	AC-2011-009	Archivo digital	Producción Científica	Artículos científicos	Disponible

Hepatic transplantation in a child with giant multicystic tumor: pathological and imaging findings / María Elsy Sepúlveda Hincapie ; Nora Luz Yepes Palacio ; Sergio Iván Hoyos Duque  

Público ISBD Título : Hepatic transplantation in a child with giant multicystic tumor: pathological and imaging findings Tipo de documento : documento electrónico Autores : María Elsy Sepúlveda Hincapie, ; Nora Luz Yepes Palacio, ; Sergio Iván Hoyos Duque, Fecha de publicación : 2010 Títulos uniformes : Pediatric Transplantation Idioma : Francés (fre) Palabras clave : Hepatic  cystic  tumor  transplantation  pathological  imaging Resumen : A 30 month old male white child presented with 13 months of increasing abdominal girth. The MRI and MDCT showed a giant heterogeneous and predominantly cystic mass with thick and nodular septation, measuring approximately 18, 15, 20 cm, which occupied almost the whole liver. A histological diagnosis was not possible, which necessitated transplantation. One year after transplantation the course has been satisfactory without recurrence and with normal hepatic function and negative tumor markers Mención de responsabilidad : Germán A Castrillon, Elsy Sepúlveda, Nora L Yepez, Sergio Hoyos, Germán Osorio Referencia : Pediatr Transplantation 2010 Aug;14(5):e58-61. DOI (Digital Object Identifier) : 10.1111/j.1399-3046.2009.01166.x PMID : 19413715 En línea : https://onlinelibrary.wiley.com/doi/10.1111/j.1399-3046.2009.01166.x Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3545 Hepatic transplantation in a child with giant multicystic tumor: pathological and imaging findings [documento electrónico] / María Elsy Sepúlveda Hincapie, ; Nora Luz Yepes Palacio, ; Sergio Iván Hoyos Duque,  . - 2010. Obra : Pediatric Transplantation Idioma : Francés (fre) Palabras clave : Hepatic  cystic  tumor  transplantation  pathological  imaging Resumen : A 30 month old male white child presented with 13 months of increasing abdominal girth. The MRI and MDCT showed a giant heterogeneous and predominantly cystic mass with thick and nodular septation, measuring approximately 18, 15, 20 cm, which occupied almost the whole liver. A histological diagnosis was not possible, which necessitated transplantation. One year after transplantation the course has been satisfactory without recurrence and with normal hepatic function and negative tumor markers Mención de responsabilidad : Germán A Castrillon, Elsy Sepúlveda, Nora L Yepez, Sergio Hoyos, Germán Osorio Referencia : Pediatr Transplantation 2010 Aug;14(5):e58-61. DOI (Digital Object Identifier) : 10.1111/j.1399-3046.2009.01166.x PMID : 19413715 En línea : https://onlinelibrary.wiley.com/doi/10.1111/j.1399-3046.2009.01166.x Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3545

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000115	AC-2010-047	Archivo digital	Producción Científica	Artículos científicos	Disponible